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Key Messages
 Metabolic changes occurring in type 1 diabetes mellitus (T1DM) patients may lead to tissue hypoxia, chronic inflammation, and
atherosclerosis.
 Hyperbaric oxygen therapy (HBOT) exerts anti-inflammatory and antiatherogenic effects on T1DM patients.
 HBOT has beneficial effects in T1DM through changes in lipid profile and plasma fatty acid composition and expression of insulin
growth factor binding protein 1.a r t i c l e i n f o
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Objective: Metabolic changes in type 1 diabetes mellitus (T1DM) impair vasodilation, and this leads to
tissue hypoxia and microvascular pathology. Hyperbaric oxygen therapy (HBOT) can significantly
improve the outcome of ischemic conditions in T1DM patients and reduce vascular complications. The
aim of our study was to assess the effects of HBOT on plasma fatty acid (FA) composition, and expression
of insulin-like growth factor binding protein 1 (IGFBP-1) in T1DM patients.
Methods: Our study included 24 adult T1DM patients diagnosed with peripheral vascular complications.
The patients were exposed to 10 sessions of 100% oxygen inhalation at 2.4 atmosphere absolute for
1 hour. Blood samples were collected at admission and after HBOT for measurement of metabolic
parameters, FA composition and IGFBP-1. Measurement of plasma FA composition was determined by gas
chromatography. Expression of IGFBP-1 in the serum was estimated by Western blot analysis.
Results: HBOT decreased blood levels of total cholesterol (p<0.05), triglycerides (p<0.05) and
low-density lipoprotein (p<0.05). HBOT increased plasma levels of individual FAs: palmitic acid
(p<0.05), palmitoleic acid (p<0.05), docosapentaenoic acid (p<0.05) and docosahexaenoic acid (p<0.01),
and decreased levels of stearic acid (p<0.05), alpha linolenic acid (p<0.05) and linoleic acid (p<0.01).
Expression of IGFBP-1 (p<0.01) was increased, whereas the level of insulin (p<0.001) was decreased in
the serum after HBOT.
Conclusions: Our results indicate that HBOT exerts beneficial effects in T1DM patients by improving the
lipid profile and altering FA composition.
 2019 Canadian Diabetes Association.c and Esma R. Isenovic PhD, Institute of Nuclear Sciences Vinca, Laboratory of Radiobiology and Molecular Genetics,
erbia.
novic@yahoo.com




protéine de liaison au facteur de
croissance insulinomimétique de type 1
diabète de type 1
r é s u m é
Objectif : Les modifications du métabolisme lors du diabète de type 1 (DT1) nuisent à la vasodilation et,
par conséquent, entraînent une hypoxie tissulaire et une pathologie microvasculaire. L’oxygénothérapie
hyperbare (OHB) peut améliorer de manière significative l’évolution des maladies d’origine ischémique
chez les patients atteints du DT1 et réduire les complications vasculaires. L’objectif de notre étude était
d’évaluer les effets de l’OHB sur la composition plasmatique des acides gras (AG) et l’expression de laI. Resanovic et al. / Can J Diabetes 44 (2020) 22e29 23lipides
complications vasculairesprotéine de liaison au facteur de croissance insulinomimétique de type 1 (IGFBP-1, de l’anglais insulin-like
growth factor binding protein 1) chez les patients atteints du DT1.
Méthodes : Notre étude regroupe 24 patients adultes atteints du DT1 qui ont reçu un diagnostic de
complications vasculaires périphériques. Nous avons fait subir aux patients 10 séances d’inhalation
d’oxygène à 100 % à une pression atmosphérique absolue de 2,4 durant 1 heure. Nous avons effectué la
collecte d’échantillons de sang à l’admission et après l’OHB pour mesurer les paramètres métaboliques, la
composition des AG et l’IGFBP-1. Nous avons déterminé la composition plasmatique des AG au moyen de
la chromatographie en phase gazeuse. Nous avons estimé l’expression de l’IGFBP-1 dans le sérum à l’aide
de l’immunobuvardage de western.
Résultats : L’OHB diminuait les concentrations sanguines du cholestérol total (p < 0,05), des triglycérides
(p < 0,05) et des lipoprotéines à faible densité (p < 0,05). L’OHB augmentait les concentrations plas-
matiques individuelles des acides gras, soit l’acide palmitique (p < 0,05), l’acide palmitoléique (p < 0,05),
l’acide docosapentaénoïque (p < 0,05) et l’acide docosahexaénoïque (p < 0,01), et diminuait les con-
centrations de l’acide stéarique (p < 0,05), de l’acide alpha-linolénique (p < 0,05) et de l’acide linoléique
(p < 0,01). Nous avons noté une augmentation de l’expression de l’IGFBP-1 (p < 0,01), mais une dimi-
nution de la concentration de l’insuline (p < 0,001) dans le sérum après l’OHB.
Conclusions : Nos résultats indiquent que l’OHB exerce des effets bénéfiques chez les patients atteints de
DT1 puisqu’elle permet d’améliorer le profil des lipides et de modifier la composition des AG.
 2019 Canadian Diabetes Association.Introduction
Type 1 diabetes mellitus (T1DM) is characterized by the
destruction of insulin-secreting pancreatic beta cells under the
influence of genetic and/or environmental factors (1). Factors
involved in T1DM pathogenesis trigger lymphocyte infiltration in
pancreatic beta cells, and various proinflammatory cytokines
responsible for the destruction of pancreatic beta cells are
produced (2). Metabolic changes occurring in T1DM patients
may lead to chronic inflammation and atherosclerosis (3).
Hyperglycemia is one of the major risk factors in the development
of vascular complications due to consequent tissue hypoxia and
insufficient tissue nutrition in T1DM patients (3).
Fatty acids (FAs) are structural components of triglycerides
(TGs), phospholipids and cholesterol esters. Changes in FA
composition influence cells by modifying membrane properties,
altering intracellular signalling pathways and gene expression (4).
A link between inflammation, altered FA composition and type 2
diabetes mellitus (T2DM) has been demonstrated (5). An elevated
level of n-3 polyunsaturated FA (PUFA) may lower the risk of
destruction of pancreatic beta cells and reduce inflammation by
inhibiting secretion of proinflammatory cytokines and lymphocyte
proliferation in T1DM patients (6,7). In addition, the elevated level
of n-3 PUFA in plasma phospholipids has positive effects on glucose
and lipid metabolism, which prevents the progression of
arteriosclerosis in T1DM and T2DM (8). Evidence shows that
changes of n-3 PUFA level in themembrane phospholipidsmay be a
useful therapeutic approach for inflammation and the vascular
complications that occur in T1DM (9).
Insulin-like growth factor 1 (IGF-1) plays a major role in glucose
metabolism by lowering insulin level, increasing insulin sensitivity
and improving the lipid profile, and thus affecting cardiovascular
physiology (10,11). Altered IGF-1 activity is a major predisposing
factor in T2DM-related vascular complications and contributes to
the development of cardiovascular disorders (10,11), whereas
insulin-like growth factor binding protein 1 (IGFBP-1) has been
shown to inhibit action of IGF-1 by forming a IGF-1/IGFBP-1complex (10,11). The IGFBP-1, as a 30-kD circulatory protein, is
predominantly expressed in the liver, and IGFBP-1 protein has been
involved inmetabolic homeostasis (12). IGFBP-1 has been proposed
as a player in insulin counter-regulation (13). In contrast, insulin
inhibits the transcription of IGFBP-1 in the liver and decreases
levels of IGFBP-1 in the blood (14). Results from a cross-sectional
study showed that concentration of circulatory IGFBP-1 correlates
with insulin sensitivity (15). Data from a longitudinal study
showed that circulating IGFBP-1 concentration could predict the
development of glucose intolerance and T2DM (16). In addition,
some data also suggest that IGFBP-1 may contribute to the patho-
physiology of the cardiovascular system (17,18). The concentration
of IGFBP-1 has been shown to be inversely associated with micro-
vascular and overt macrovascular disease (17). Thus, an increase in
IGFBP-1 levels could play a role in themanagement of patients with
insulin resistance, hypertension, T2DM and other conditions with
accelerated atherosclerosis (19). When compared with T2DM, pa-
tients with T1DM demonstrated contrasting results with regard to
IGFBP-1 levels, and it was shown that high serum IGFBP-1 levels
were associated with T1DM (20).
Considering that insulin therapy does not always result in
adequate daily glycemic control and this may contribute to the
development of vascular complications, additional therapies are
needed in T1DM patients to reduce vascular complications. An ideal
treatment for the vascular complications that follow T1DM
should combine strategies aimed to reduce hyperglycemia and
inflammation, promote angiogenesis and restore functional
pancreatic beta-cell mass. Hyperbaric oxygen therapy (HBOT) is
used widely for the treatment of ischemic lesions and vascular
complication caused by T1DM and T2DM (21). The relatively
noninvasive nature and good safety profile of HBOT make it
attractive for treatment of vascular complications related to T1DM
and T2DM. HBOT includes therapeutic inhalation of 100% oxygen
under elevated pressure and, therefore, increases the level of dis-
solved oxygen available to tissues (22).
We hypothesized that exposure of T1DM patients to HBOT
would improve the lipid profile and affect FA composition and
I. Resanovic et al. / Can J Diabetes 44 (2020) 22e2924expression of IGFBP-1 and, consequently, contribute to the
reduction of vascular complications. Thus, we evaluated the effect
of HBOT on plasma lipid profile, plasma composition of FA and
expression of serum IGFBP-1 in T1DM patients.
Methods
Chemicals and reagents
Protease inhibitor (Complete, Ultra Mini, without ethylene-
diamine tetraacetic acid) and phosphatase inhibitor (PhosStop)
cocktails were obtained from Roche (Mannheim, Germany). A
GLUC-PAP commercial kit (Randox, Crumlin, United Kingdom) was
utilized. Kits for determination of total cholesterol, TG and
high-density lipoprotein (HDL) were obtained from Cobas,
Roche Diagnostics (Indianapolis, Indiana, United States), and a
radioimmunoassay kit for determination of insulin was obtained
from INEP (Belgrade, Serbia). FAmethyl ester commercial standards
(PUFA-2) used for calibration of the gas chromatography (GC)
column were obtained from Supelco (Bellefonte, Pennsylvania,
United States). Polyclonal goat anti-IGFBP-1 and antibeta-actin
antibodies were purchased from Santa Cruz Biotechnology
(Santa Cruz, California, United States). Secondary biotinylated
horse antigoat antibody was obtained from Vector Laboratories
(Burlingame, California, United States). Enhanced chemilumines-
cent (ECL) reagent was obtained from Pierce, Thermo Scientific
(Rockford, Illinois, United States).
Subjects
Our study included 24 adult T1DM patients (19 males and
5 females), 41 to 80 (62.61.7) years of age, with diagnosed
peripheral vascular complications. The patients were recruited
from the Department of Hyperbaric Medicine, Zemun Clinical
Hospital, Belgrade, Serbia, from October 2016 to December 2017.
This prospective, randomized pilot study was approved by the
ethics committee of Zemun Clinical Hospital and informed written
consent was obtained from all patients. A total of 10 sessions of
HBOTwere performed in a hyperbaric chamber (Dräger 1000/1200,
Drägerwerk AG & Co, Lübeck, Germany). Therapy was applied as 1
session/day, over a 2-week period, with 100% oxygen inhalation at
2.4 atmosphere absolute (ATA) for a 1-h duration. The demographic
properties and medical history of all patients were recorded at the
first visit, including gender, body mass, height, body mass index
(BMI), current T1DM management, hypertension, and other
concomitant therapy (aspirin, statins, fibrates, antiplatelet therapy,
angiotensin-converting enzyme inhibitors, angiotensin-receptor
blockers, calcium-channel and beta blockers). The presence of
vascular complications was confirmed by a standard questionnaire.
Serum and plasmawere immediately extracted from blood samples
collected on admission and after 10 sessions of HBOT, and then
stored at 20C until further analysis.
Measurement of serum glucose concentration
The concentration of the serum glucose was measured using the
standard GLUC-PAP method (Randox) in an Rx Daytona Automatic
Biochemical Analyzer (Randox) according to the manufacturer’s
manual. Serum blood glucose concentration was expressed in
millimoles per litre (mmol/L).
Measurement of serum insulin concentration
Serum insulin concentration was measured using a standard
insulin radioimmunoassay method (INEP) according to themanufacturer’s manual. The insulin concentrationwas expressed in
millieinternational units per litre (mIU/L).
Measurement of lipid profile
Concentrations of total cholesterol, TG and HDL cholesterol
(HDL-C) in the plasma were measured using an enzymatic
colorimetric kit according to the manufacturer’s guidelines using a
Cobas Integra 400þ analyzer (Roche Diagnostics, Indianapolis,
Indiana, United States). The concentration of HDL-C was
determined by the precipitation method with sodium
phosphowolframate/magnesium chloride. Non-HDL-C was
calculated as: total cholesterol  HDL-C. The values of low-density
lipoprotein cholesterol (LDL-C) were calculated using the
Friedewald equation: LDL-C ¼ total cholesterol  HDL  0.45  TG.
Concentrations of total cholesterol, TG, HDL-C, non-HDL-C, and
LDL-C were expressed in mmol/L and presented as fold change vs
before HBOT. In addition, we used the measured parameters to
calculate atherogenic and cardiovascular risks. Atherogenic risk
represents a logarithmically transformed lipid ratio of molar
concentrations of LDL-C to HDL-C. Cardiovascular risk is calculated
as logarithmically transformed lipid ratio of molar concentrations
of total cholesterol to HDL-C (23).
Determination of plasma FA composition
FA composition of total lipids in plasma was determined using
themethod described by Glaser et al, with slightmodifications (24).
Briefly, we added 3 mol/L hydrochloric acid mixed with methanol,
in 100 mL of plasma, with heating to 85C for 45 minutes. After
cooling to room temperature, we added 1.5 mL of hexane and
centrifuged at 1,800g for 10 minutes, then the hexane layer was
dried under a stream of nitrogen. A samplewas dissolved in 10 mL of
hexane and 1 mL was injected into the Shimadzu 2014 GC device
(Restek). The GC was equipped with a capillary column (Rtx 2330,
Restek) with an inner diameter of 60 meters  0.25 mm and film
the thickness of 0.2 mm. The temperature program was 140C to
210C for 3 minutes. Individual FAs (palmitic acid [PA, 16:0], stearic
acid [SA, 18:0], palmitoleic acid [16:1], vaccenic acid [VA, 18:1n-7],
oleic acid [OA, 18:1n-9], alpha linolenic acid [ALA, 18:3n-3],
eicosapentaenoic acid [EPA, 20:5n-3], docosapentaenoic acid
[DPA, C22:5n-3], docosahexaenoic acid [DHA, C22:6n-3], linoleic
acid [LA, 18:2n-6], gamma linolenic acid [GLA, 18:3n-6], dihomo
gamma linolenic acid [DGLA, 20:3n-6], arachidonic acid [AA,
20:4n-6] and docosatetraenoic acid [adrenic acid, AdA, 22:4n-6])
were identified according to the retention time of FA methyl ester
commercial standards (PUFA-2, Supelco). The level for each
particular FA is expressed as a percent of total FA and presented as
fold change vs before HBOT.
Sodium dodecyl sulfate polyacrylamide gel electrophoresis and
Western blotting
Serum samples were prepared by boiling for 5 minutes with the
addition of 5 Laemmli sample buffer and separated on 10%
sodium dodecyl sulfate polyacrylamide gel electrophoresis (25).
Each lane of the sodium dodecyl sulfate polyacrylamide
electrophoresis gel was loaded with 40 mg of total proteins.
Separated proteins from the serum were transferred to nitro-
cellulosemembranes, blockedwith 5% nonfatmilk and then probed
with the goat anti-IGFBP-1 antibody. The membranes were washed
and incubated with biotinylated horse antigoat antibody.
The anti-actin monoclonal antibody was used as a loading
control. Signals originating from immunoreactive proteins were
detected using electrochemiluminescent reagent. The densito-
metric analysis of protein bands was performed using ImageJ
Table 1
Anthropometric parameters and glucose level of T1DM patients at admission
Parameter Mean  SEM (n¼24)
Age (years) 62.61.7
Body mass (kg) 83.53.1
Height (m) 1.750.02
BMI (kg/m2) 27.31.1
T1DM duration (years) 16.11.4
Glucose level (mmol/L) 9.40.7
BMI, Body mass index; HBOT, hyperbaric oxygen therapy; T1DM; type 1 diabetes
mellitus; SEM, standard error of the mean.
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States). Level of IGFBP-1 is presented as fold change vs before HBOT.
Statistical analysis
Numerical variables are reported using descriptive statistics
(mean  standard error); categorical variables are reported as a
percent. SPSS 18.0 forWindows (SPSS, Chicago, Illinois, United States)
was used for all statistical calculations. Pearson’s correlation
coefficient was calculated to test correlations between C-reactive
protein (CRP) and individual FA. Differences between groups were
analyzed by Student’s t-test. Statistical significancewas set at p<0.05.
Results
Our prospective pilot study included 24 T1DM patients with
vascular complications. The anthropometric parameters and blood
glucose levels of T1DMpatients at admission are presented inTable 1.
Exposure to HBOT decreased the plasma levels of total
cholesterol by 0.15-fold vs before HBOT, p<0.05 (before HBOT/after
HBOT: 1 to 5.7/0.7 to 2.5 mmol/L) (Figure 1A); non-HDL-C by
0.22-fold vs before HBOT, p<0.05 (before HBOT/after HBOT: 0.5 to
4.2/0.4 to 2 mmol/L) (Figure 1B); TG by 0.18-fold vs before HBOT,
p<0.05 (before HBOT/after HBOT: 0.3 to 1.9/0.2 to 1.2 mmol/L)
(Figure 1C); and LDL-C by 0.22-fold vs before HBOT, p<0.05 (before
HBOT/after HBOT: 0.4 to 3.6/0.2 to 1.5 mmol/L) (Figure 1D). HDL-C
level was unchanged (before HBOT/after HBOT: 0.2 to 0.9/0.2
to 1 mmol/L) (Figure 1E). The calculated atherogenic and
cardiovascular risks for T1DM patients show that exposure to HBOT
decreased atherogenic risk (p<0.05), whereas no significant
influence on cardiovascular risk was detected (Figure 1, inset).
Regarding plasma FA composition, exposure to HBOT did not
change the level of total plasma saturated FA (SFA), although HBOT
increased the level of PA (p<0.05) and decreased the level of SA
(p<0.05). Exposure to HBOT did not changed the level of total
monounsaturated FA (MUFA) and specific MUFA: VA and OA,
whereas the level of palmitoleic acid increased significantly after
HBOT (p<0.05). In addition, the level of total n-3 PUFA and specific
n-3 PUFA EPA did not change after exposure to HBOT. Furthermore,
HBOT increased levels of DPA (p<0.05) and DHA (p<0.01) and
decreased plasma level of ALA (p<0.05). Exposure to HBOT did not
change the level of total n-6 PUFA nor the level of specific n-6 PUFA:
GLA, DGLA, AA, and AdA. However, HBOT decreased the level of LA
(p<0.01) in the plasma of T1DM patients (Table 2). In previous
work, we found that CRP decreased after exposure to HBOT in
T1DM patients (26). To evaluate the relationship between CRP and
FA composition, we performed linear relationship analysis
(Table 2). The results show a significant correlation between CRP
and DHA after exposure to HBOT (r ¼ þ0.508, p<0.05).
Expression of IGFBP-1 in the serum samples was analyzed by
Western blotting. Results show that exposure to HBOT increased
IGFBP-1 expression by 0.5-fold vs before HBOT, p<0.01 (Figure 2A).
We also assessed insulin in the serum of T1DM patients and found
that insulin level decreased after HBOT by 0.3-fold vs before HBOT,p<0.001 (before HBOT: 37.15.6 mIU/L; after HBOT: 21.93.8
mIU/L) (Figure 2B).
Discussion
This is the first report of the effects of HBOT on FA composition
and expression of IGFBP-1 in T1DM patients. Our findings suggest
that: 1) HBOT induced an increase in the level of PA, palmitoleic
acid, DPA and DHA, and a significant decrease in SA, ALA and LA in
the plasma of T1DM patients; 2) HBOT induced an increase in
IGFBP-1 level and 3) HBOT affected the lipid profile. The T1DM
patients with vascular complications were exposed to HBOT, which
has previously been associated with a significant reduction in
T1DM by inhibiting apoptosis of pancreatic beta cells in a T1DM
mouse model (27). However, some of the beneficial effects of HBOT
remain controversial and the exact mechanisms of action are still
unclear. A deeper understanding of the molecular mechanisms
involved in HBOTmay improve and fine-tune treatment of vascular
complications related to T1DM and lead to recognition of new
molecular targets for T1DM treatment.
T1DM patients are prone to abnormalities in the lipid profile,
such as high levels of plasma TG and LDL-C, and low levels of HDL-C
(28). These abnormalities may lead to enhanced lipoprotein
susceptibility to oxidation, altered FA composition and lipoprotein
density and increased lipid glycosylation (28). The impaired lipid
profile observed in T1DM patients could be explained by
hyperglycemia, but also by peripheral hyperinsulinemia caused by
the subcutaneous insulin administration (29). Changes in glucose
and lipid metabolism may further suppress autophagy, implicated
in the progression of T2DM and development of microvasculature
abnormalities (30). Consistent with data from other studies (28,31),
we found that HBOT decreased plasma levels of TG and LDL-C. The
high level of non-HDL-C has been associated with increased risk of
vascular complications in T1DM patients (32). We observed a
decrease of non-HDL-C and total cholesterol level in the plasma
after HBOT. Sun et al reported that an increased level of
lipoproteins and decreased level of HDL-C was associated with a
higher incidence of cardiovascular disease (33). However, we did
not find any significant effect of HBOT on the level of HDL-C,
probably due to other parameters, such as age and diet (34,35).
Another reason for not detecting a significant effect on HDL-C could
lie in the small sample size and small effect size. Eleftheriou et al
observed that the lipid profile and overall atherogenic and
cardiovascular risk factors were pronounced in T1DM patients (36).
We found that HBOT led to a significant decrease in atherogenic risk
and a nonsignificant decrease in cardiovascular risk, consistent
with previous observations (37). As it is well known that elevated
levels of TG and LDL-C, and atherogenic risk are directly related to
vascular complications (31), our results suggest that exposure to
HBOT improves the lipid profile in T1DM patients.
Because the abnormalities in the plasma FA composition are
related to poor glycemic control (38), and interactions between FA
and glucose may cause oxidative stress and lead to inflammation in
T1DM and T2DM (39), we aimed to evaluate whether exposure of
T1DM patients to HBOT has an effect on plasma FA composition. In
addition, considering that FA may act as either a pro- or anti-
inflammatory factor, depending on their chemical structure (4),
we assessed levels of SFA, MUFA, and PUFA in plasma using the GC
method. Grimble et al reported a link between altered FA compo-
sition and inflammation in lymphocytes (40). Results from our
previous study (26) suggest that the anti-inflammatory effects of
HBOT may be linked to the reduction in nuclear factor kappaB (NF-
kB) and, consequently, to the reduction of activity and expression of
inducible nitric oxide synthase in T1DM patients, so we aimed to
evaluate whether HBOT exerts an additional anti-inflammatory













































































































































Figure 1. Effect of HBOT on lipid profile in the plasma of T1DM patients. (A) Level of total cholesterol in plasma, expressed as fold change vs before HBOT (arbitrary control set
at 1). (B) Level of non-HDL in plasma, expressed as fold change vs before HBOT (arbitrary before HBOT set at 1). (C) Level of TG in plasma, expressed as fold change vs before
HBOT (arbitrary before HBOT set at 1). (D) Level of LDL in plasma, expressed as fold change vs before HBOT (arbitrary before HBOT set at 1). (E) Level of HDL in the
plasma, expressed as fold change vs before HBOT (arbitrary before HBOT set at 1). Inset: Atherogenic and cardiovascular risk assessment after HBOT (n¼21e23); *p<0.05.
HBOT, Hyperbaric oxygen therapy; HDL, high-density lipoprotein; T1DM, type 1 diabetes mellitus; LDL, low-density lipoprotein; n.s., not statistically significant; TG,
triglyceride.
I. Resanovic et al. / Can J Diabetes 44 (2020) 22e2926The literature data show that T1DM patients have increased SFA
levels in the plasma (38). We have found that HBOT did not
change the total amount of SFA in plasma, although it
significantly changed the level of specific SFAsdincreasing the level
of PA and decreasing the level of SA. Increased levels of PA and SA
can trigger an inflammatory response by increasing secretion of
proinflammatory cytokines and expression of transcription factorsTable 2






SFA 40.60.3 40.30.4 n.s.
Palmitic acid (16:0) 27.10.3 28.10.3 <0.05
Stearic acid (18:0) 13.30.2 12.40.2 <0.05
MUFA 16.70.4 17.00.5 n.s.
Palmitoleic acid (16:1) 1.30.1 1.70.1 <0.05
Vaccenic acid (18:1n-7) 1.60.1 1.60.1 n.s.
Oleic acid (18:1n-9) 13.40.4 14.20.4 n.s.
n-3 PUFA 3.50.2 3.80.1 n.s.
Alpha linolenic acid (18:3n-3) 0.30.04 0.20.02 <0.05
Eicosapentaenoic acid (20:5n-3) 0.50.05 0.50.04 n.s.
Docosapentaenoic acid (22:5n-3) 0.50.02 0.60.03 <0.05
Docosahexaenoic acid (22:6n-3) 2.10.1 2.50.1 <0.01
n-6 PUFA 392.1 38.72.1 n.s.
Linoleic acid (18:2n-6) 25.30.04 23.20.04 <0.01
Gamma linolenic acid (18:3n-6) 0.80.04 0.80.01 n.s.
Dihomo gamma linolenic acid
(20:3n-6)
2.90.3 3.30.2 n.s.
Arachidonic acid (20:4n-6) 10.50.4 10.50.3 n.s.
Docosatrienoic acid (22:4n-6) 0.40.03 0.40.02 n.s.
Correlation analysis of CRP (mg/L)
and docosahexaenoic acid
(% of total FA) after HBOT
(n¼23)
r¼þ0.508 <0.05
CRP, C-reactive protein; FA, fatty acid; HBOT, hyperbaric oxygen therapy; MUFA,
monounsaturated fatty acid; n.s., not statistically significant; PUFA, polyunsaturated
fatty acid; SEM, standard error of the mean; SFA, saturated fatty acid; T1DM, type 1
diabetes mellitus.
Note. Data are expressed as percent of plasma total FAs (mean  SEM).involved in inflammation, such as NF-kB (41). This profile, with
increased levels of PA and SA, is often found in metabolic disorders
and is considered unfavourable because PA has higher atherogenic
potential than SA (42). In contrast, our results show that HBOT had
no effect on the total amount of MUFA, whereas the level of
palmitoleic acid was significantly increased. Talbot et al reported
that, even the presence of an individual MUFA, palmitoleic acid is
sufficient to prevent inflammatory activity induced by PA (43).
These results suggest that exposure of T1DM patients to HBOT
could be in part responsible for a reduction in inflammatory
response triggered by PA in plasma.
Our findings show that exposure of T1DM patients to HBOT did
not change the total amount of n-3 PUFA, but it significantly
increased the level of DPA and DHA and decreased the level of ALA.
This decrease in ALA level could be explained by the effect of HBOT
on the induction of higher conversion of ALA to longer chain n-3
PUFA, considering also that ALA is a well-known precursor for
synthesis of n-3 series PUFAs, such as DPA and DHA (42). Because
we observed an increased conversion of ALA to DPA and DHA in
plasma after HBOT, it would be of interest for our future work to
explore the synergistic effect of treatment with n-3 PUFA
supplementation and HBOT. Furthermore, in our previous study
(26), we observed that the level of CRP was reduced after HBOT in
T1DM patients. In the current study, we observed a significant
correlation between CRP and DHA level in T1DM patients after
HBOT. These results suggest that exposure of T1DM patients to
HBOT leads to a reduction of inflammation and slowed progression
of atherosclerosis. Recent studies indicated that an elevated level of
DHA exerted strong anti-inflammatory and cardioprotective effects
in the plasma of T2DM patients (44,45), and reduced inflammation
by decreasing the generation of reactive oxygen species, production
of proinflammatory cytokines and transcription of genes encoding
proteins involved in the inflammatory response (e.g. NF-kB) (6,9).
Also, an increased level of DHA is associated with a less atherogenic
profile of LDL, by increasing the LDL size and reducing levels of TG,
thus improving vascular function (46). Our results show that HBOT

































































Figure 2. Effects of HBOT on the serum levels of IGFBP-1 and insulin in T1DM patients. (A) Level of IGFBP-1 in the serum, expressed as fold change of before HBOT (arbitrary control
set at 1). (B) Level of insulin in the serum, expressed as fold change of before HBOT (arbitrary control set at 1). Inset: Representative Western blot (n¼20). ***p<0.001; **p<0.01.
HBOT, Hyperbaric oxygen therapy; IGFBP-1, insulin-like growth factor binding protein 1; T1DM, type 1 diabetes mellitus.
I. Resanovic et al. / Can J Diabetes 44 (2020) 22e29 27exerts similar effects as dietary intake of long-chain n-3 PUFAs,
which is of great interest in the context of their anti-inflammatory
and antioxidative properties.
Because most of the n-6 PUFAs are well-known promoters of
inflammation, and a strong association between level of n-6 PUFA
and T2DMwas observed (47), we also evaluated the level of total n-
6 PUFA in T1DM patients after exposure to HBOT. We found that
HBOT significantly decreased the plasma level of a specific n-6
PUFA, LA. Considering that increased LA can alter the function of
proteins, increase the production of reactive oxidative spaces (48)
and stimulate the transcription of NF-kB (49), and also
considering our current and previous results (26), we suggest that
HBOT modifies signalling pathways and transcription factors
involved in the inflammatory response by changing the FA
composition in T1DM patients. Changes in FA composition caused
by HBOT may be partially responsible for the beneficial effects of
HBOT on the vascular function of T1DM patients. The mechanism
by which HBOT exerts its effects on FA composition is still unclear.
However, Brown et al showed that HBOT at 2.2 ATA stimulated
synthesis and elongation of FAs, and also changed the relative
amounts of individual FAs in membranes by affecting enzymes
involved in FA syntheses, such as elongase and desaturase (50). In
the current study, we also found that after HBOT relative activity of
elongase enzyme was increased (data not shown).
It was shown that insulin and IGF-1 with its binding proteins
play an important role in the pathophysiology of vascular
complications in T1DM and T2DM (51,52). Therefore, we aimed to
explore the effect of HBOT on levels of insulin and IGFBP-1 in the
blood. Our findings demonstrate that the insulin level was signifi-
cantly decreased after exposure to HBOT. This effect of HBOT in
T1DM patients could be explained by better T1DM control in the
hospital environment, including prepared meals with specified
portions and caloric intake and the absence of everyday stress. In
addition, numerous studies in T1DM and T2DM patients showed
that HBOT may improve insulin sensitivity, followed by decreased
blood glucose levels (53e56). Beneficial effects of HBOT in foot
ulcer healing or early beneficial effects on peripheral blood vessels’
endothelial layer function can significantly decrease hyperglyce-
mia, as these can be the source of poor T1DM and T2DM control
(55,56). A positive influence of HBOT on control of T1DM may have
led to the reduced insulin requirements, but the underlying
mechanisms of HBOT effects in T1DM require further investigation.
IGFBP-1 has a major role in lipid and glucose metabolism,
namely IGFBP-1, decreases lipid accumulation in different cells andenhances glucose uptake in peripheral tissues (57). Increased levels
of IGFBP-1 are associated with vascular complications in T1DM
patients (58). Because HBOT is known to reduce vascular
complications in T1DM and T2DM patients (21), one of the aims of
our study was to investigate whether HBOT affects the level of
IGFBP-1 in the serum of T1DM patients. Surprisingly, we found that
IGFBP-1 level was increased after HBOT. Regulation of IGFBP-1 is
dependent on several factors, but themost important is insulin, and
hepatic production of IGFBP-1 is inversely regulated by insulin in
the circulation (58). The reduced level of insulin after HBOT
observed in our study could be a reason for the increased level of
IGFBP-1. Also, the aforementioned HBOT effects occur early, so at
this time we cannot speculate on the further direction of serum
IGFBP-1 change. However, conflicting results from other studies
(58) exploring the effects of IGFBPs in T1DM and the lack of data on
HBOT effects on IGFBPs levels call for further investigation, espe-
cially with regard to delayed effects. According to genetic studies,
some additional epigenetic analyses of the IGFBP-1 gene may
elucidate the link between the change in IGFBP-1 level and micro/
macrovascular complications in T1DM patients (20).
This study has several limitations. As this was a pilot study, we
recruited T1DM patients with different comorbidities and
concomitant diseases and various drugs used for their
management, and we observed wide individual variability in the
parameters measured. Also, we included T1DM patients of both
genders, with the exception of menstruating women (to exclude
the beneficial effects of estrogen on vascular endothelium). Also,
the number of patients was small, and we did not have any specific
information about dietary data on the patients studied. We also
recognize and appreciate that those interindividual variations in
diet, medications, lifestyle, smoking and other environmental
exposures can influence the FA composition of plasma
phospholipids. Because of the small number of patients included in
our study, we were unable to confirm definitively the effect of
HBOT. In future work, we plan to recruit a larger number of T1DM
patients to follow up all parameters assessed in this study after 10
HBOT treatments to estimate the long-term effects of the therapy.
We also plan to follow up fluctuations of the studied parameters
after each treatment to establish the minimum number of
treatments needed to obtain beneficial effects in T1DM patients
with vascular complications. Further study is necessary to elucidate
the effects of confounding factors and more clearly outline the
molecular mechanisms of HBOT’s effects on the vascular
endothelium.
I. Resanovic et al. / Can J Diabetes 44 (2020) 22e2928In conclusion, in this work, we have identified a significant
HBOT effect on FA composition and IGFBP-1 expression in T1DM
patients. Based on our results, we suggest that HBOT exerts
anti-inflammatory and antiatherogenic effects in T1DM patients,
probably by a mechanism that involves changes in the lipid profile
and plasma FA composition. The improvement seen in these
patients after HBOT can contribute to a reduction in vascular
complications. Our study is the first to examine the effects of HBOT
on FA composition and IGFBP-1, and these observations deserve
more attention and additional research. Future studies on a larger
population and including dietary information are needed to better
understand the molecular mechanism by which HBOT regulates FA
composition and reduces vascular complications in T1DM patients.
Both frequency and dose of HBOT still need to be determined to
identify the maximum efficiency and minimum side effects in the
treatment of T1DM patients.
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